ReviewJournal of molecular medicine (Berlin, Germany)2013
DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer.
Review in Journal of molecular medicine (Berlin, Germany), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 92 citations in OpenAlex.
- KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability.iScience · 2026Article
- A novel prognostic biomarker for colorectal cancer: the ratio of red cell distribution width to lymphocytes.Scientific reports · 2026Article
- LINC00634 is a novel prognostic biomarker for colon cancer associated with immune infiltration.BMC gastroenterology · 2025Article
- Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring.Molecular cancer · 2024Review
- Promising predictive molecular biomarkers for cervical cancer (Review).International journal of molecular medicine · 2024Review
- Detection of caudal type homeobox 1 (Journal of genetics · 2024Article
- Detecting colorectal cancer using genetic and epigenetic biomarkers: screening and diagnosis.Journal of medicine and life · 2024Review
- Role of hypermethylated SLC5A8 in follicular thyroid cancer diagnosis and prognosis prediction.World journal of surgical oncology · 2023Article
- A novel screening method of DNA methylation biomarkers helps to improve the detection of colorectal cancer and precancerous lesions.Cancer medicine · 2023Article
- Correlation of NPDC1 Expression and Perineural Invasion Status with Clinicopathological Features in Patients with Colon Cancer.International journal of general medicine · 2023Article
- Diagnostic and therapeutic biomarkers in colorectal cancer: a review.American journal of cancer research · 2022Review
- Identification of DNA methylation markers for early detection of CRC indicates a role for nervous system-related genes in CRC.Clinical epigenetics · 2021Article
- High-Yield Methylation Markers for Stool-Based Detection of Colorectal Cancer.Digestive diseases and sciences · 2020Article
- Multiple gene promoter methylation and clinical stage in adjacent normal tissues: Effect on prognosis of colorectal cancer in Taiwan.Scientific reports · 2020Article
- Epigenetic profiling of MUTYH, KLF6, WNT1 and KLF4 genes in carcinogenesis and tumorigenesis of colorectal cancer.BioMedicine · 2019Article
- Genome-wide DNA methylation analysis of colorectal adenomas with and without recurrence reveals an association between cytosine-phosphate-guanine methylation and histological subtypes.Genes, chromosomes & cancer · 2019Article
- Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer-From Basic Research to Potential Clinical Applications.International journal of molecular sciences · 2019Review
- BioMethyl: an R package for biological interpretation of DNA methylation data.Bioinformatics (Oxford, England) · 2019Article
- Polycystins and Mechanotransduction in Human Disease.International journal of molecular sciences · 2019Review
- "Same difference": comprehensive evaluation of four DNA methylation measurement platforms.Epigenetics & chromatin · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most common type of cancer and is responsible for 9 % of cancer deaths in both men and women in the USA for 2013. It is a heterogenous disease, and its three classification types are microsatellite instability, chromosomal instability, and CpG island methylator phenotype. Biomarkers are molecules, which can be used as indicators of cancer. They have the potential to achieve great sensitivities and specificities in diagnosis and prognosis of CRC. DNA methylation biomarkers are epigenetic markers, more specifically genes that become silenced after aberrant methylation of their promoter in CRC. Some methylation biomarkers like SEPT9 (ColoVantage®) and vimentin (ColoSure(TM)) are already commercially available. Other blood and fecal-based biomarkers are currently under investigation and clinical studies so that they can be used in the near future. Biomarker panels are also currently being studied since they show great potential in diagnosis as they can combine robust biomarkers to achieve even greater sensitivities than single markers. Finally, methylation-sensitive microRNAs (miRNAs) are very promising markers, and their investigation as biomarkers, is only at primitive stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.